Calciphylaxis in kidney graft recipient with type 1 diabetes: A case report

Abstract

Calcifylaxis — calcifying uremic arteriolopathy — is a rare disease that occurs in patients with chronic kidney disease and is characterized by progressive calcification of small-caliber skin vessels and thrombosis of small (arterioles), accompanied by necrosis of the skin, subcutaneous tissue and soft tissues with severe pain syndrome. The article describes a patient with a long-term, severe course of diabetes mellitus, the development of diabetic nephropathy with an outcome in terminal renal failure, which required renal replacement therapy with peritoneal dialysis and kidney transplantation. In the posttransplantation period, the patient registered the occurrence of calcifylaxis, which is a rare complication.

The lack of treatment protocols for calcifylaxis in patients with chronic kidney disease requires further research. It is important to constantly monitor patients with risk factors for the development of this serious disease and timely treatment, which will improve their condition and slow down the progression of the process.

Keywords

calcifylaxis / calcifying uremic arteriolopathy / chronic kidney disease / diabetic nephropathy / secondary hyperparathyroidism

References

[1] Podestà MA, Ciceri P, Galassi A, Cozzolino M. Calciphylaxis after kidney transplantation: a rare but life-threatening disorder. Clin Kidney J. 2022;15(4):611–614. DOI: 10.1093/ckj/sfab247

[2] Podestà M.A., Ciceri P., Galassi A., Cozzolino M. Calciphylaxis after kidney transplantation: a rare but life-threatening disorder // Clin. Kidney J. 2022. Vol. 15, No. 4. P. 611–614. DOI: 10.1093/ckj/sfab247

[3] Abbas H, Alotaibi M, Lebron R. A case report: Calciphylaxis presenting as digital ischemia in patient with end stage kidney disease on peritoneal dialysis. Open J Nephrol. 2019;9:49–53. DOI: 10.4236/ojneph.2019.92006

[4] Abbas H., Alotaibi M., Lebron R. A case report: Calciphylaxis presenting as digital ischemia in patient with end stage kidney disease on peritoneal dialysis // Open J. Nephrol. 2019. Vol. 9. P. 49–53. DOI: 10.4236/ojneph.2019.92006

[5] Nigwekar SU, Zhao S, Wenger J, et al. A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol. 2016;27(11):3421–3429. DOI: 10.1681/ASN.2015091065

[6] Nigwekar S.U., Zhao S., Wenger J. et al. A nationally representative study of calcific uremic arteriolopathy risk factors // J. Am. Soc. Nephrol. 2016. Vol. 27, No. 11. P. 3421–3429. DOI: 10.1681/ASN.2015091065

[7] Baby D, Upadhyay M, Joseph MD, et al. Calciphylaxis and its diagnosis. J Family Med Prim Care. 2019;8(9):2763–2767. DOI: 10.4103/jfmpc.jfmpc_588_19

[8] Baby D., Upadhyay M., Joseph M.D. et al. Calciphylaxis and its diagnosis // J. Family Med. Prim. Care. 2019. Vol. 8, No. 9. P. 2763–2767. DOI: 10.4103/jfmpc.jfmpc_588_19

[9] Ryan MP, Ross LS. Calciphylaxis after kidney transplant. Cureus. 2019;11(5):e4695. DOI: 10.7759/cureus.4695

[10] Ryan M.P., Ross L.S. Calciphylaxis after kidney transplant // Cureus. 2019. Vol. 11, No. 5. P. e4695. DOI: 10.7759/cureus.4695

[11] Gabel CK, Nguyen ED, Chakrala T, et al. Assessment of outcomes of calciphylaxis. J Am Acad Dermatol. 2021;85(4):1057–1064. DOI: 10.1016/j.jaad.2020.10.067

[12] Gabel C.K., Nguyen E.D., Chakrala T. et al. Assessment of outcomes of calciphylaxis // J. Am. Acad. Dermatol. 2021. Vol. 85, No. 4. P. 1057–1064. DOI: 10.1016/j.jaad.2020.10.067

[13] Shuman H, Obri MS, Artz C, et al. Nonuremic calciphylaxis precipitated by COVID-19 infection. Cureus. 2022;14(3):e22796. DOI: 10.7759/cureus.22796

[14] Shuman H., Obri M.S., Artz C. et al. Nonuremic calciphylaxis precipitated by COVID-19 infection // Cureus. 2022. Vol. 14, No. 3. P. e22796. DOI: 10.7759/cureus.22796

[15] Nigwekar SU, Kroshinsky D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis, and treatmen. Am J Kidney Dis. 2015;66(1):133–146. DOI: 10.1053/j.ajkd.2015.01.034

[16] Nigwekar S.U., Kroshinsky D., Nazarian R.M. et al. Calciphylaxis: risk factors, diagnosis, and treatmen // Am. J. Kidney Dis. 2015. Vol. 66, No. 1. P. 133–146. DOI: 10.1053/j.ajkd.2015.01.034

[17] Guillén E, Torregrosa JV, Garcia-Herrera A, et al. Development of calciphylaxis in kidney transplant recipients with a functioning graft. Clin Kidney J. 2021;15(4):663–671. DOI: 10.1093/ckj/sfab205

[18] Guillén E., Torregrosa J.V., Garcia-Herrera A. et al. Development of calciphylaxis in kidney transplant recipients with a functioning graft // Clin. Kidney J. 2021. Vol. 15, No. 4. P. 663–671. DOI: 10.1093/ckj/sfab205

[19] Nefrologiya. Klinicheskie rekomendatsii. Ed. by E.M. Shilov, A.V. Smirnov, N.L. Kozlovskaya. Moscow; 2019. P. 736–740 p. (In Russ.)

[20] Нефрология. Клинические рекомендации / под ред. Е.М. Шилова, А.В. Смирнова, Н.Л. Козловской. Москва, 2019. С. 736–740.

[21] Brandenburg V, Adragao T, van Dam B, et al. Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). Clin Kidney J. 2015;8:567–571. DOI: 10.1093/ndt/gfv438

[22] Brandenburg V., Adragao T., van Dam B. et al. Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet) // Clin. Kidney J. 2015. Vol. 8. P. 567–571. DOI: 10.1093/ndt/gfv438

[23] Nigwekar SU, Zhao S, Wenger J, et al. A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol. 2016;27:3421–3429. DOI: 10.1681/ASN.2015091065

[24] Nigwekar S.U., Zhao S., Wenger J. et al. A nationally representative study of calcific uremic arteriolopathy risk factors // J. Am. Soc. Nephrol. 2016. Vol. 27. P. 3421–3429. DOI: 10.1681/ASN.2015091065

[25] Brandenburg VM, Kramann R, Rothe H, et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant. 2017;32(1):126–132. DOI: 10.1093/ndt/gfv438

[26] Brandenburg V.M., Kramann R., Rothe H. et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry // Nephrol. Dial. Transplant. 2017. Vol. 32, No. 1. P. 126–132. DOI: 10.1093/ndt/gfv438

[27] Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, et al. Treatment of calciphylaxis in CKD: a systematic review and meta-analysis. Kidney Int Rep. 2018;4(2):231–244. DOI: 10.1016/j.ekir.2018.10.002

[28] Udomkarnjananun S., Kongnatthasate K., Praditpornsilpa K. et al. Treatment of calciphylaxis in CKD: a systematic review and meta-analys // Kidney Int. Rep. 2018. Vol. 4, No. 2. P. 231–244. DOI: 10.1016/j.ekir.2018.10.002

[29] Kodumudi V, Jeha GM, Mydlo N, Kaye AD. Management of cutaneous calciphylaxis. Adv Ther. 2020;37(12):4797–4807. DOI: 10.1007/s12325-020-01504-w

[30] Kodumudi V., Jeha G.M., Mydlo N., Kaye A.D. Management of cutaneous calciphylaxis // Adv. Ther. 2020. Vol. 37, No. 12. P. 4797–4807. DOI: 10.1007/s12325-020-01504-w

[31] Gaisne R, Péré M, Menoyo V, et al. Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study. BMC Nephrol. 2020;21(1):63. DOI: 10.1186/s12882-020-01722-y

[32] Gaisne R., Péré M., Menoyo V. et al. Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study // BMC Nephrol. 2020. Vol. 21, No. 1. P. 63. DOI: 10.1186/s12882-020-01722-y

[33] Jeong HS, Dominguez AR. Calciphylaxis: controversies in pathogenesis, diagnosis and treatment. Am J Med Sci. 2016;351(2):217–227. DOI: 10.1016/j.amjms.2015.11.015

[34] Jeong H.S., Dominguez A.R. Calciphylaxis: controversies in pathogenesis, diagnosis and treatment // Am. J. Med. Sci. 2016. Vol. 351, No. 2. P. 217–227. DOI: 10.1016/j.amjms.2015.11.015

[35] Sinha S, Gould LJ, Nigwekar SU, et al. The CALCIPHYX study: a randomized, double-blind, placebo-controlled, phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. Clin Kidney J. 2022;15:136–144. DOI: 10.1093/ckj/sfab117

[36] Sinha S., Gould L.J., Nigwekar S.U. et al. The CALCIPHYX study: a randomized, double-blind, placebo-controlled, phase 3 clinical trial of SNF472 for the treatment of calciphylaxis // Clin. Kidney J. 2022. Vol. 15. P. 136–144. DOI: 10.1093/ckj/sfab117

[37] Ricardo VB, Egido J. Phosphate, pyrophosphate, and vascular calcification: a question of balance. Eur Heart J. 2017;38(23):1801–1804. DOI: 10.1093/eurheartj/ehv605

[38] Ricardo V.B., Egido J. Phosphate, pyrophosphate, and vascular calcification: a question of balance // Eur. Heart J. 2017. Vol. 38, No. 23. P. 1801–1804. DOI: 10.1093/eurheartj/ehv605

[39] Egshatyan LV, Mokrysheva NG. Ectopic calcification in chronic kidney disease. Part 1. Classification and pathogenesis. Nephrology (Saint-Petersburg). 2017;21(4):30–39. (In Russ.) DOI: 10.24884/1561-6274-2017-21-4-30-39

[40] Егшатян Л.В., Мокрышева Н.Г. Эктопическая кальцификация при хронической болезни почек. Часть 1. Классификация и патогенез // Нефрология. 2017. Т. 21, № 4. С. 30–39. DOI: 10.24884/1561-6274-2017-21-4-30-39

[41] Ruderman I, Toussaint ND, Hawley CM, et al. The Australian calciphylaxis registry: reporting clinical features and outcomes of patients with calciphylaxis. Nephrol Dial Transplant. 2021;36:649–656. DOI: 10.1093/ndt/gfz256

[42] Ruderman I., Toussaint N.D., Hawley C.M. et al. The Australian calciphylaxis registry: reporting clinical features and outcomes of patients with calciphylaxis // Nephrol. Dial. Transplant. 2021. Vol. 36. P. 649–656. DOI: 10.1093/ndt/gfz256

[43] Musso CG, Enz PA, Kowalczuk A, et al. Differential diagnosis of calciphylaxis in chronic dialysis patients. Int Urol Nephrol. 2020;52(3):595–597. DOI: 10.1007/s11255-020-02388-z

[44] Musso C.G., Enz P.A., Kowalczuk A. et al. Differential diagnosis of calciphylaxis in chronic dialysis patients // Int. Urol. Nephrol. 2020. Vol. 52, No. 3. P. 595–597. DOI: 10.1007/s11255-020-02388-z

[45] Westphal SG, Plumb T. Calciphylaxis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

[46] Westphal S.G., Plumb T. Calciphylaxis // StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.

[47] Yu WY, Bhutani T, Kornik R, et al. Warfarin-associated nonuremic calciphylaxis. JAMA Dermatol. 2017;153(3):309–314. DOI: 10.1001/jamadermatol.2016.4821

[48] Yu W.Y., Bhutani T., Kornik R. et al. Warfarin-associated nonuremic calciphylaxis // JAMA Dermatol. 2017. Vol. 153, No. 3. P. 309–314. DOI: 10.1001/jamadermatol.2016.4821

[49] Cianciolo G, Capelli I, Angelini ML, et al. Importance of vascular calcification in kidney transplant recipients. Am J Nephrol. 2014;39:418–426. DOI: 10.1159/000362492

[50] Cianciolo G., Capelli I., Angelini M.L. et al. Importance of vascular calcification in kidney transplant recipients // Am. J. Nephrol. 2014. Vol. 39. P. 418–426. DOI: 10.1159/000362492

[51] Ponticelli C, Glassock RJ. Prevention of complications from use of conventional immunosuppressants: a critical review. J Nephrol. 2019;32(6):851–870. DOI: 10.1007/s40620-019-00602-5

[52] Ponticelli C., Glassock R.J. Prevention of complications from use of conventional immunosuppressants: a critical review // J. Nephrol. 2019. Vol. 32, No. 6. P. 851–870. DOI: 10.1007/s40620-019-00602-5

[53] Guillén E, Torregrosa JV, Garcia-Herrera A, et al. Development of calciphylaxis in kidney transplant recipients with a functioning graft. Clin Kidney J. 2022;15(4):663–671. DOI: 10.1093/ckj/sfab205

[54] Guillén E., Torregrosa J.V., Garcia-Herrera A. et al. Development of calciphylaxis in kidney transplant recipients with a functioning graft // Clin. Kidney J. 2022. Vol. 15, No. 4. P. 663–671. DOI: 10.1093/ckj/sfab205

RIGHTS & PERMISSIONS

Eco-Vector